For how we live.
Two doses of an MF59-adjuvanted, cell-based H5N8 vaccine raised antibodies in most of 239 adults, including those over 65. It is a pandemic-preparedness candidate, not evidence that it prevents disease.
In the KALUMI trial, children with uncomplicated malaria got ganaplacide plus a new lumefantrine formulation or standard artemether-lumefantrine. Cure rates at day 29 were 99% in both groups.
Final FDA guidance published on 3 November says blood collectors need not test whole-blood donations for hepatitis B surface antigen when nucleic-acid and anti-core tests are run, keeping both for Source Plasma.
A CDC-journal review identified six confirmed Cryptococcus gattii infections during 2016–2024, five of one genotype in western Nova Scotia and four in people who had never left the province — a sign of local acquisition.
A phase 4 trial in 400 Indian adults compared a 1-week intradermal post-exposure schedule with the month-long one. Antibody levels fell short of the equivalence margin, though everyone reached the protective threshold.
The agency authorised emergency use of four veterinary products to prevent or treat New World screwworm infestations, acting on a 2025 declaration that the parasite poses a potential public-health emergency.
A new 30-day order under the Public Health Service Act continues suspending the entry of certain travellers recently in DR Congo, Uganda or South Sudan. It runs through 10 November; comments close 30 October.
Hovilpri (pritelivir), a helicase-primase inhibitor, was approved on 9 October for immunocompromised adults whose herpes lesions resist aciclovir. In its trial, 63% healed by day 28 against 34% on comparator therapy.
A final order published 9 October classifies systems that let people collect their own specimens for non-viral STI testing as class II, moving them out of the automatic class III that demands premarket approval.
A 28-year-old technician at a plague research institute in Irkutsk died on 2 October. WHO rates the risk low in Russia and very low in Europe, but has asked Russian authorities to clarify the cause of her pneumonia.
A Toronto cohort reports that an eight-day antiviral protocol prevented or cleared hepatitis C in all 116 recipients of organs from infected donors, with survival matching recipients of uninfected organs.
A nationwide Brazilian cohort of 4.1 million children found that babies exposed to Zika in the womb but without congenital Zika syndrome had the same pneumonia-hospitalisation risk as unexposed children.
An IARC worldwide incidence analysis puts the infection-attributable share at 12%, led by H pylori and HPV, with eastern Asia carrying the heaviest load and most of the toll preventable.
Rezzayo's once-weekly echinocandin can now be used in adolescents with candidaemia who have few other options. The expansion rests on adult data and modelling, not on studies in children.
There is still no licensed Lyme vaccine. In a phase 2 trial of VLA15, a second yearly booster revived antibody levels against all six OspA serotypes, with more sore arms but no new safety signals.
In the SNAP platform trial, cefazolin was non-inferior to flucloxacillin or cloxacillin for 90-day survival in methicillin-susceptible S. aureus bacteraemia, and caused notably less acute kidney injury.
In the SOLARIO trial, patients who got local antibiotics at surgery did no worse on a short systemic course than a long one, and reported far fewer side effects. The comparison was independently funded.
Urinary infections in men were long treated as automatically complicated. A randomised trial found seven days of antibiotics non-inferior to fourteen, and guidelines say not to treat urine that causes no symptoms.
In the TESEO trial, benznidazole for 30 days matched the 60-day standard for clearing the parasite and caused fewer side effects, pointing to a gentler regimen for a neglected disease.
An observational study across four DR Congo outbreak sites estimates that a third of positive mpox PCR results reflect environmental viral DNA, not infection — and that a stricter cutoff fixes most of it.
A study of 46 pathogens attributes about 66,400 child deaths in 2023 to Streptococcus pneumoniae across G20 countries, with the heaviest load falling on India, South Africa and Indonesia.
England's scarlet fever rate tripled after 2014 and a more toxigenic strep A lineage emerged, culminating in the deadly 2022 wave of invasive infections in children.
Around 60–70% of infants carry Clostridioides difficile without illness. A Science study finds its toxins remodel the newborn gut in mice — but the direct human evidence is still limited to cells and biopsies.
The childhood infection clears on its own in most children and has no specific antiviral. The evidence that matters is about the rare severe case — and where it happens.
A systematic review of the Syrian crisis and infectious disease in Lebanon names overcrowding, poor sanitation and blocked healthcare access — not the presence of refugees themselves — as the reported drivers.
A narrative review synthesising WHO, UNRWA and Gaza health-ministry field data reports the re-emergence of hepatitis A and poliovirus, over 200,000 diarrhoeal cases, and drug-resistant hospital pathogens.
Vibrio vulnificus wound infections rose eightfold along the Eastern US between 1988 and 2018, and a 2026 model projects recreational-water infection risk climbing up to a thousandfold by 2100.
In the LATITUDE trial, monthly cabotegravir–rilpivirine injections cut regimen failure to 22.8% from 41.2% on oral therapy among people with a history of missed doses, prompting an early stop.
A Lancet study across 547,000 adults and 925 infectious diseases finds obesity raises the risk of severe infection across almost every pathogen type. The global estimate rests on modelling, not on the cohorts themselves.